Oglobine J - Search Results

1

[Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].

Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Bouchet C, et al. Among authors: oglobine j. Bull Cancer. 1994 Sep;81(9):770-9. Bull Cancer. 1994. PMID: 7703566 French.

2

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J. Foucré D, et al. Among authors: oglobine j. Br J Cancer. 1991 Nov;64(5):926-32. doi: 10.1038/bjc.1991.428. Br J Cancer. 1991. PMID: 1931618 Free PMC article.

3

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Bouchet C, et al. Among authors: oglobine j. Br J Cancer. 1994 Feb;69(2):398-405. doi: 10.1038/bjc.1994.74. Br J Cancer. 1994. PMID: 8297742 Free PMC article.

4

Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.

Romain S, Spyratos F, Lainé-Bidron C, Bouchet C, Guirou O, Martin PM, Oglobine J, Magdelénat H. Romain S, et al. Among authors: oglobine j. Eur J Clin Chem Clin Biochem. 1995 Sep;33(9):603-8. Eur J Clin Chem Clin Biochem. 1995. PMID: 8611670

5

Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues.

Bouchet-Bernet C, Spyratos F, Andrieu C, Deytieux S, Bécette V, Oglobine J. Bouchet-Bernet C, et al. Among authors: oglobine j. Breast Cancer Res Treat. 1996;41(2):141-6. doi: 10.1007/BF01807159. Breast Cancer Res Treat. 1996. PMID: 8944332

6

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Bouchet C, Spyratos F, Hacène K, Durcos L, Bécette V, Oglobine J. Bouchet C, et al. Among authors: oglobine j. Br J Cancer. 1998 May;77(9):1495-501. doi: 10.1038/bjc.1998.246. Br J Cancer. 1998. PMID: 9652768 Free PMC article.

7

Dissemination risk index based on plasminogen activator system components in primary breast cancer.

Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Bouchet C, et al. Among authors: oglobine j. J Clin Oncol. 1999 Oct;17(10):3048-57. doi: 10.1200/JCO.1999.17.10.3048. J Clin Oncol. 1999. PMID: 10506599

8

[Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].

Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Bouchet C, et al. Among authors: oglobine j. Pathol Biol (Paris). 2000 Nov;48(9):825-31. Pathol Biol (Paris). 2000. PMID: 11141918 French.

9

Competitive prognostic value of clinicopathologic and bioimmunologic factors in primary breast cancer.

Hacene K, Desplaces A, Brunet M, Lidereau R, Bourguignat A, Oglobine J. Hacene K, et al. Among authors: oglobine j. Cancer. 1986 Jan 15;57(2):245-50. doi: 10.1002/1097-0142(19860115)57:2<245::aid-cncr2820570210>3.0.co;2-2. Cancer. 1986. PMID: 3484657

10

Tissue glycolytic enzymes in primary breast cancer patients receiving adjuvant chemotherapy.

Spyratos F, Oglobine J, Lidereau R, Hacene K, Brault C, Desplaces A. Spyratos F, et al. Among authors: oglobine j. Eur J Cancer Clin Oncol. 1986 Jan;22(1):21-7. doi: 10.1016/0277-5379(86)90338-x. Eur J Cancer Clin Oncol. 1986. PMID: 3956556

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters